Enhanced clearance of Candida albicans from the oral cavities of mice following oral administration of Lactobacillus acidophilus

Clinical and Experimental Immunology

Volumn 141, Issue 1, 2005, Pages 29-36

  Elahi, S ^a   Pang, G ^b   Ashman, R ^c   Clancy, Robert ^b,d  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF NEWCASTLE   (Australia)

^c UNIVERSITY OF QUEENSLAND   (Australia)

^d UNIVERSITY OF NEWCASTLE   (Australia)

Author keywords

C. albicans; Cytokine; Lactobacilli; Nitric oxide

Indexed keywords

CANDIDA ANTIGEN; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 4; MESSENGER RNA; NITRIC OXIDE; PROBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CELL FREE SYSTEM; CERVICAL LYMPH NODE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FUNGAL COLONIZATION; IMMUNOSTIMULATION; LACTOBACILLUS ACIDOPHILUS; LACTOBACILLUS FERMENTUM; MALE; MOUSE; MOUTH CAVITY; NONHUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVA ANALYSIS; STATISTICAL ANALYSIS;

ADMINISTRATION, ORAL; ANIMALS; CANDIDA ALBICANS; CANDIDIASIS, ORAL; CYTOKINES; GENE EXPRESSION; IMMUNITY, MUCOSAL; LACTOBACILLUS ACIDOPHILUS; LYMPH NODES; MALE; MICE; MICE, INBRED DBA; MOUTH; NECK; NITRIC OXIDE; PROBIOTICS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SALIVA;

EID: 21344469688     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2005.02811.x     Document Type: Article

References (38)

1. Epstein J, Truelove E, Izutau K. Oral candidiasis: pathogenesis and host defence. Rev Infect Dis 1984; 6:96-106.
2. McCarthy GM. Host factors associated with HIV-related oral candidiasis. A review. Oral Surg Oral Med Oral Pathol 1992; 73:181-6.
3. Odds FC. Candida and candidosis. Baltimore, MD: University Park Press, 1988:104-10.
4. Samaranayake LP. Host factors and oral candidiasis. London: Wright, 1990:66-103.
5. Myerowitz RL, Pazin GJ, Allen CM. Disseminated candidiasis. changes in incidence, underlying diseases, and pathology. Am J Clin Pathol 1977; 68:29-38.
6. Greenfield RD. Host defence system interaction with Candida. J Med Vet Mycol 1992; 30:89-104.
7. d) mice. Oral Microbiol Immunol 1994; 9:88-94.
8. Elahi S, Pang G, Ashman RB, Clancy R. Cellular and cytokine correlates of mucosal protection in a murine model of oral candidiasis. Infect Immun 2000; 68:5771-7.
9. Lacasse M, Fortier C, Chakir J, Cote L, Deslaurieres N. Acquired resistance and persistence of C. albicans following oral candidiasis in the mouse: a model of the carrier state in humans. Oral Microbiol Immunol 1993; 8:313-18.
10. Elahi S, Pang G, Ashman RB, Clancy R. Nitric oxide enhanced resistance to oral candidiasis. Immunology 2001; 104:447-54.
11. Elahi S, Clancy R, Pang G. A therapeutic vaccine for mucosal candidiasis. Vaccine 2001; 19:2516-21.
12. Perdigon G, de Macias EN, Alvarez S, Oliver G, Pesce de Ruiz Holgado A. Effect of perorally administered Lactobacilli on macrophage activation in mice. Infect Immun 1986; 53:404-10.
13. Schiffrin EJ, Rochat F, Link-Amster H, Aeschlimann JM, Donnet-Hughes A. Immunomodulation of human blood cells following the ingestion of lactic acid bacteria. J Dairy Sci 1994; 78:491-7.
14. Heumann D, Barras C, Severin A, Glauser MP, Tomasz A. Gram-positive cell walls stimulate synthesis of tumour necrosis factor alpha and interleukin-6 by human monocytes. Infect Immun 1994; 62:2715-21.
15. Kalo I, Tanaka K, Yokokura T. Lactic acid bacterium potently induces the production of interleukin-12 and IFN-gamma by mouse splenocytes. Int J Immunopharmacol 1999; 21:121-31.
16. Marin ML, Tejada-Simon MV, Lee JH, Murtha J, Ustunol Z, Pestka JJ. Cytokine production in macrophage and T-cell models by Streptococcus thermophilus: comparison with Bifidobacterium sp. and Lactobacillus bulgaricus. J Food Prot 1998; 61:859-64.
17. Miettinen M, Matikainen S, Vuopio-Varkila J et al. Lactobacilli and streptococci induce IL-12, IL-18 and gamma interferon production in human peripheral blood mononuclear cells. Infect Immun 1998; 66:6058-62.
18. Nicaise P, Gleizes A, Forestier F, Quero A, Labarre M. Influence of intestinal bacterial flora on cytokine (IL-1, IL-6 and TNF-alpha) production by mouse peritoneal macrophages. Eur Cytokine Netw 1993; 4:133-8.
19. Tejada-Simon MV, Ustunol Z, Pestka JJ. Ex vivo effects of lactobacilli, streptococci, and bifidobacteria ingestion on cytokine and nitric oxide production in a murine model. J Food Prot 1999; 62:162-9.
20. Link-Amster H, Rochat F, Saudan K, Mignot O, Aeschlimann JM. Modulation of a specific humoral immune response and changes in intestinal flora mediated through fermented milk intake. FEMS Immunol Med Microbiol 1994; 10:55-63.
21. Phaupradit P, Varavithya W, Vathanophas K et al. Reduction of rotavirus infection in children receiving bifidobacteria-supplemented formula. J Med Assoc Thai 1999; 82:43-8.
22. Saavedra JM, Bauman NA, Oung I, Perman JA, Yolken RH. Feeding of Befidobacterium bifidum and Streptococcus thermophilis to infants in hospital for prevention of diarrhoea and shedding of rotavirus. Lancet 1994; 344:1046-9.
23. Perdigon G, Alvarez S, Pesce de Ruiz Holgado A. Immunoadjuvant activity of oral L. casei: influence of dose on the secretory immune response and protective capacity in intestinal infections. J Dairy Res 1991; 58:485-96.
24. Wagner RD, Pierson C, Warner T et al. Biotherapeutic effects of probiotic bacteria on candidiasis in immunodefident mice. Infect Immun 1997; 65:4165-72.
25. Wagner RD, Pierson C, Warner T, Dohnalek M, Hilty M, Balish E. Probiotic effects of feeding heat-killed L. acidophilus and L. casei to C. albicans-colonized immunodeficient mice. J Food Prot 2000; 63:638-44.
26. Hilton E, Isenberg HD, Alperstein P, France K. Ingestion of yogurt containing L. acidophilus as prophylaxis for Candida vaginitis. Ann Intern Med 1992; 116:353-7.
27. Green LC, Wagner DA, Glogowski J, Skipper PL, Wishnok JS, Tannenbaum SR. Analysis of nitrate and nitrite in biological fluids. Anal Biochem 1982; 126:131-44.
28. Fernandez MF, Boris S, Barbes C. Probiotic properties of human lactobacilli strains to be used in the gastrointestinal tract. J Appl Microbiol 2003; 94:449-55.
29. Mercenier A, Pavan S, Pot B. Probiotics as biotherapeutic agents: present knowledge and future prospects. Curr Pharm Des 2003; 9:175-91.
30. Clancy R. Immunobiotics and the probiotic evolution. FEMS Immunol Med Microbiol 2003; 38:9-12.
31. Cross ML. Immune-signalling by orally-delivered probiotic bacteria: effects on the common mucosal immune responses and protectio at distal mucosal sites. Int J Immunopathol Pharmacol 2004; 17:127-34.
32. Shanahan F. Probiotics; a perspective on problems and pitfalls. Scand J Gastroenterol 2003; 38(Suppl. 237):34-36.
33. De Petrino SF, De Jorrat MEBB, Meson O, Perdigon G. Protective ability of certain lactic acid bacteria against an infection with C. albicans in a mouse immunosuppression model by corticoid. Food Agric Immunol 1995; 7:365-73.
34. Wagner RD, Warner T, Farmer J, Roberts L, Balish E. Colonization of congenitally immunodeficient mice with probiotic bacteria. Infect Immun 1997; 65:3345-51.
35. Rachmilewitz D, Katakura K, Karmeli F et al. Toll-like receptor 9 signalling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology 2004; 126:520-8.
36. Roman M, Martin-Orozco E, Goodman JS et al. Immunostimulatory DNA sequences function as T helper-1-promoting adjuvants. Nat Med 1997; 3:849-54.
37. Horner AA, Ronaghy A, Cheng PM et al. Immunostimulatory DNA is a potent mucosal adjuvant. Cell Immunol 1998; 190:77-82.
38. Majamaa M, Isolauria E, Saxelin M, Vesikari T. Lactic acid bacteria in the treatment of acute rotavirus gastroenteritis. J Pediatr Gastroenterol Nutr 1995; 20:330-8.